| Quality assessment | No of patients | Effect | Quality | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Treatment versus no treatment | Control | Relative (95% CI) | Absolute | ||
| Stroke (diastolic) - >80mmHg (follow-up mean 4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | very serious1 | serious2 | none |
735/21807 (3.4%) |
943/20792 (4.5%) | RR 0.74 (0.68 to 0.82) | 12 fewer per 1000 (from 8 fewer to 15 fewer) |
⨁◯◯◯ VERY LOW | CRITICAL |
| Stroke (diastolic) - 80–84mmHg (follow-up mean 4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | very serious1 | serious2 | none |
393/18780 (2.1%) |
516/18736 (2.8%) | RR 0.76 (0.67 to 0.87) | 7 fewer per 1000 (from 4 fewer to 9 fewer) |
⨁◯◯◯ VERY LOW | CRITICAL |
| Stroke (diastolic) - 85–89mmHg (follow-up mean 4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | very serious1 | no serious imprecision | none |
709/23105 (3.1%) |
749/16626 (4.5%) | RR 0.68 (0.62 to 0.75) | 14 fewer per 1000 (from 11 fewer to 17 fewer) |
⨁⨁◯◯ LOW | CRITICAL |
| Stroke (diastolic) - 90–94mmHg (follow-up mean 4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | very serious1 | no serious imprecision | none |
399/19368 (2.1%) |
631/19278 (3.3%) | RR 0.63 (0.56 to 0.71) | 12 fewer per 1000 (from 9 fewer to 14 fewer) |
⨁⨁◯◯ LOW | CRITICAL |
| Stroke (diastolic) - >95mmHg (follow-up mean 4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | very serious1 | no serious imprecision | none |
123/3331 (3.7%) |
209/2864 (7.3%) | RR 0.51 (0.41 to 0.63) | 36 fewer per 1000 (from 27 fewer to 43 fewer) |
⨁⨁◯◯ LOW | CRITICAL |
Downgraded by 1 increment due to population or outcome indirectness, or by 2 increments for both population and outcome indirectness.
Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.
From: Evidence review for initiating treatment
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.